UiPath Inc
Technology
UiPath Inc (PATH) Stock News
The latest PATH headlines and market coverage — 8 recent stories, updated throughout the day.
- Zacks Investment Research·
Here's Why UiPath (PATH) Is a Great 'Buy the Bottom' Stock Now
UiPath (PATH) stock has declined 7% over the past week but formed a hammer chart pattern suggesting potential trend reversal. The technical signal is supported by fundamental strength, including a 24.1% increase in consensus EPS estimates over the last 30 days and a Zacks Rank #2 (Buy) rating, indicating analyst optimism about the enterprise automation software developer's future earnings.
- GlobeNewswire Inc.·
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.
- Zacks Investment Research·
PATH's 21% Rise in Million-Dollar Customers is the Number to Watch
UiPath's million-dollar customer base grew 21% to 387 customers, significantly outpacing the 10% growth in its broader $100,000+ ARR customer segment. This indicates deeper enterprise penetration and stronger adoption of automation solutions. However, UiPath faces intensifying competition from Pegasystems and ServiceNow as enterprise demand for AI and workflow automation expands.
- Zacks Investment Research·
UiPath Slides 24% After Q2 Earnings: Is PATH Stock a Buy?
UiPath shares dropped 24% following Q2 fiscal 2027 results that beat revenue expectations and included raised full-year guidance. Despite strong fundamentals including 12.5% ARR growth, fourth consecutive GAAP profitability, and AI appearing in 18 of 20 largest deals, investors focused on modest Q3 guidance and restrained ARR increases. Analysts view the selloff as creating an attractive entry point for patient investors, rating the stock a Buy.
- Zacks Investment Research·
UiPath (PATH) Meets Q2 Earnings Estimates
UiPath reported Q2 2026 earnings of $0.15 per share, matching consensus estimates, with revenues of $410.26 million exceeding expectations by 3.19%. The stock has underperformed the S&P 500 year-to-date, gaining 9.8% versus the market's 12%. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market. The Internet-Software industry ranks in the top 31% of Zacks industries.
- Zacks Investment Research·Neutral
Exploring Analyst Estimates for UiPath (PATH) Q2 Earnings, Beyond Revenue and EPS
Wall Street analysts predict UiPath will report Q2 earnings of $0.15 per share (flat year-over-year) with revenues of $397.59 million (+9.9% YoY). Key metrics show subscription services revenue at $271.07 million (+13.7% YoY), ARR reaching $1.93 billion, and dollar-based net retention rate at 109%. The stock has gained 42.2% over the past month and holds a Zacks Rank #3 (Hold) rating.
- GlobeNewswire Inc.·
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.
- GlobeNewswire Inc.·
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion announced positive Phase 2 pediatric study results showing bempedoic acid (NEXLETOL) safely reduced LDL-C by 6-25% in children aged 6-17 with familial hypercholesterolemia. Additionally, a secondary analysis of CLEAR Outcomes found that 42% of statin-intolerant patients achieved ≥30% LDL-C reduction at 3 months, with enhanced results in women, patients with higher baseline LDL-C, and those using concurrent ezetimibe.